secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001641172-25-023110
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA's Ketamir-2 manuscript accepted for publication; shows superior efficacy in neuropathic pain models
--------------------------------------------------------------------------------

- Ketamir-2 manuscript accepted in Frontiers in Pharmacology; outperformed ketamine, pregabalin, gabapentin in preclinical models.
- Restored sensory function and reversed pain behaviors across genders and species in two validated models.
- Global neuropathic pain market: $7.97B (2024) projected to $16.79B by 2034, CAGR 7.73%; North America ~$3.7-3.9B.
- Company plans to submit Phase 2a protocol to FDA in Q4 2025, aiming to initiate study by year-end.
- Also evaluating Ketamir-2 for depression, anxiety, PTSD, and as a topical formulation for localized pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225023110/0001641172-25-023110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225023110/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer